Filtered By:
Drug: Aspirin
Procedure: Heart Valve Surgery
This page shows you your search results in order of date.
Order by Relevance | Date
Total 64 results found since Jan 2013.
Edoxaban versus Dual Antiplatelet Therapy for Leaflet Thrombosis and Cerebral Thromboembolism after TAVR: The ADAPT-TAVR Randomized Clinical Trial
Conclusions: In patients without an indication for long-term anticoagulation after successful TAVR, the incidence of leaflet thrombosis was numerically lower with edoxaban than with DAPT, but this was not statistically significant. The effect on new cerebral thromboembolism and neurological or neurocognitive function were also not different between two groups. Because the study was underpowered, the results should be considered hypothesis-generating, highlighting the need for further research.PMID:35373583 | DOI:10.1161/CIRCULATIONAHA.122.059512
Source: Circulation - April 4, 2022 Category: Cardiology Authors: Duk-Woo Park Jung-Min Ahn Do-Yoon Kang Kyung Won Kim Hyun Jung Koo Dong Hyun Yang Seung Chai Jung Byungjun Kim Yiu Tung Anthony Wong Cheung Chi Simon Lam Wei-Hsian Yin Jeng Wei Yung-Tsai Lee Hsien-Li Kao Mao-Shin Lin Tsung-Yu Ko Won-Jang Kim Se Hun Kang S Source Type: research
Low-Dose Versus Standard Warfarin After Mechanical Mitral Valve Replacement: A Randomized Controlled Trial
CONCLUSIONS: Low-dose warfarin was noninferior to standard-dose warfarin in patients with an On-X mechanical mitral prosthesis, following >3 postoperative months of standard anticoagulation therapy. (PROACT Clinicaltrials.gov number, NCT00291525).PMID:35101419 | DOI:10.1016/j.athoracsur.2022.01.015
Source: The Annals of Thoracic Surgery - February 1, 2022 Category: Cardiovascular & Thoracic Surgery Authors: Michael W A Chu Marc Ruel Allen Graeve Marc W Gerdisch Ralph J Damiano Robert L Smith William Brent Keeling Michael A Wait Robert C Hagberg Reed D Quinn Gulshan K Sethi Rosario Floridia Christopher J Barreiro Andrew L Pruitt Kevin D Accola Francois Dagena Source Type: research
Factor Xa Inhibitors for Patients after Mechanical Heart Valve Replacement?
Thorac Cardiovasc Surg. 2021 Dec 11. doi: 10.1055/s-0041-1736242. Online ahead of print.ABSTRACTPatients with a mechanical heart valve need a lifelong anticoagulation due to the increased risk of valve thrombosis and thrombo-embolism. Currently, vitamin K antagonists (VKA) are the only approved class of oral anticoagulants, but relevant interactions and side effects lead to a large number of patients not achieving the optimal therapeutic target international normalized ration (INR). Therefore, steady measurements of the INR are imperative to ensure potent anticoagulation within a distinctive range. Direct oral anticoagulan...
Source: The Thoracic and Cardiovascular Surgeon - December 11, 2021 Category: Cardiovascular & Thoracic Surgery Authors: Stephen Gerfer Maria Grandoch Thorsten C W Wahlers Elmar W Kuhn Source Type: research
